{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=11",
    "query": {
      "intervention": "Vehicle solution",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 454,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T01:01:00.779Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04113109",
      "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LCZ 696",
          "type": "DRUG"
        },
        {
          "name": "Icatibant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Para-aminohippurate",
          "type": "DRUG"
        },
        {
          "name": "Iohexol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-11-01",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04113109"
    },
    {
      "nct_id": "NCT07140783",
      "title": "OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vision Loss Night",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "0.75% Phentolamine Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2025-09-02",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 20,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 16 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07140783"
    },
    {
      "nct_id": "NCT06700070",
      "title": "A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Soft Tissue Sarcoma Adult",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PBA-0111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pure Biologics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-03-27",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06700070"
    },
    {
      "nct_id": "NCT00624845",
      "title": "Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "OMS103HP",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2007-12",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624845"
    },
    {
      "nct_id": "NCT02874846",
      "title": "Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil ophthalmic solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-07",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02874846"
    },
    {
      "nct_id": "NCT06369675",
      "title": "Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erythema"
      ],
      "interventions": [
        {
          "name": "MOB015B",
          "type": "DRUG"
        },
        {
          "name": "0.2% SLS",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        },
        {
          "name": "MOB015B vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moberg Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2017-10-19",
      "completion_date": "2017-11-14",
      "has_results": false,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369675"
    },
    {
      "nct_id": "NCT04293185",
      "title": "A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "bb1111",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "2 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-02-14",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04293185"
    },
    {
      "nct_id": "NCT01960010",
      "title": "A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "MIM-D3 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mimetogen Pharmaceuticals USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 403,
      "start_date": "2013-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 5,
      "location_summary": "Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960010"
    },
    {
      "nct_id": "NCT04638660",
      "title": "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dim Light Vision Disturbances"
      ],
      "interventions": [
        {
          "name": "Phentolamine Ophthalmic Solution 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Ophthalmic Solution Vehicle (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2020-12-30",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 17,
      "location_summary": "Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pittsburg",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04638660"
    },
    {
      "nct_id": "NCT05759208",
      "title": "The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OK-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Okyo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-28",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-10-20T01:01:00.779Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759208"
    }
  ]
}